Opthea Limited completes enrollment for 1 of 2 Phase 3 sozinibercept (OPT-302) trials
February 19th 2024The clinical-stage biopharmaceutical company is running 2 Phase 3 clinical trials, COAST and ShORe, to assess the efficacy and safety of using combinations of certain drugs to treat wet age-related macular degeneration.
EnVision Summit 2024: How women in eye care can navigate a personal IPO journey
February 16th 2024Marsha Link, PhD, uses three words—Imagine, Prepare, and Optimize—to encourage women to assess their current leadership journey, strategically plan for advancement, and explore new opportunities for growth and impact in vision care.